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Gestational diabetes mellitus (GDM) is one of the most common diseases associated with pregnancy, 
however, the underlying mechanisms remain unclear. Based on the well documented role of 
inflammation in type 2 diabetes, the aim was to investigate the role of inflammation in GDM. We 
established a mouse model for GDM on the basis of its two major risk factors, obesity and aging. In 
these GDM mice, we observed increased Interleukin-1β (IL-1β) expression in the uterus and the placenta 
along with elevated circulating IL-1β concentrations compared to normoglycemic pregnant mice. 
Treatment with an anti-IL-1β antibody improved glucose-tolerance of GDM mice without apparent 
deleterious effects for the fetus. Finally, IL-1β antagonism showed a tendency for reduced plasma 
corticosterone concentrations, possibly explaining the metabolic improvement. We conclude that IL-1β 
is a causal driver of impaired glucose tolerance in GDM.
Gestational diabetes mellitus (GDM) is one of the most common pregnancy accompanying diseases. GDM is 
defined as glucose intolerance with the onset or first recognition during pregnancy1 and usually disappears after 
giving birth2. It was estimated that GDM affects 18.4 million pregnancies and 14% of all live births worldwide2,3. 
The incidence of GDM is associated with overweight and increased age of mothers, affecting 26% of pregnant 
women older than 45 years3 and 39% of pregnant women with a BMI ≥29 kg/m2 4.
GDM is an independent risk factor for multiple complications including preeclampsia5, birth complications 
due to macrosomia, neonatal hypoglycaemia, jaundice6, and for life-long risk for obesity and type 2 diabetes mel-
litus (T2DM), the latter for both, the children and the mothers7–9.
However, so far, the pathogenesis of GDM is not well understood. During a normal pregnancy, maternal insu-
lin resistance is increased10,11, probably to facilitate glucose transport to the growing fetus. This is accompanied by 
increased maternal insulin production10,12. GDM is characterized by even more pronounced insulin resistance, 
accompanied by an insufficient increase in insulin production to overcome insulin resistance12,13.
In addition, GDM is associated with an imbalance of various immunological processes occurring during preg-
nancy. Cytokines including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) as 
well as inflammatory markers such as C-reactive protein (CRP) are increased in the circulation of obese pregnant 
women and women with GDM14–16. Conversely, IL-1 receptor antagonist (IL-1Ra), an endogenous competitive 
inhibitor of IL-1 signaling, is decreased in plasma of women with GDM17. This indicates a particular relevance 
of the master cytokine IL-1β, which can induce IL-6, TNF-α and CRP18,19. Furthermore, obese pregnant women 
have more inflammatory macrophages and an altered natural killer cell profile in the placenta compared to lean 
pregnant women20,21.
IL-1β is well known for its role in T2DM. Obesity-induced insulin resistance is mediated through inflamma-
tory factors, including TNF-α and IL-1β22–24. In obese subjects and patients with T2DM, IL-1β secretion, pre-
sumably from tissue-resident macrophages25, is increased in insulin-sensitive tissues23. It is also known that IL-1β 
is upregulated in pancreatic islets of patients with T2DM26,27. In rodents, it contributes to β-cell glucotoxicity and 
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lipotoxicity, which lead to β-cell destruction and dedifferentiation28–30. In clinical trials, IL-1Ra improved gly-
caemia and insulin secretion in patients with T2DM31,32. Moreover, the CANTOS trial involving 10’061 patients 
showed that IL-1β antagonism with canakinumab, a neutralizing anti-IL-1β antibody, is effective in reducing the 
glycated hemoglobin (HbA1c) during the first 6 months of treatment in patients with a history of myocardial 
infarction33,34. After 6 months, the glucose lowering effect remained visible only in the non-diabetic population, 
while in patients with diabetes the effect was lost due to change in diabetes medication. A recent meta-analysis of 
all 2921 reported cases with T2DM undergoing anti-IL-1 treatment demonstrated a significant (p < 0.05) reduc-
tion in HbA1c32.
Insulin resistance is partly mediated by steroid hormones such as cortisol, progesterone and estradiol, of which 
serum concentrations are increased during pregnancy and even further increased in patients with GDM35,36 The 
placenta is a production tissue of these steroid hormones and other insulin resistance-inducing hormones35,37. 
Interestingly, IL-1β has been shown to stimulate the production of various steroid hormones: it stimulates the 
production of progesterone from a human placental cell line38 and bovine granulosa cells39. In rodents, IL-1β 
increases serum corticosterone by stimulation of the hypothalamus, pituitary, adrenal (HPA) axis40–43, resulting 
in increased corticosteroid synthesis. Conversely, IL-1Ra inhibits stress-induced corticosterone production44, 
which underlines the link between IL-1 and steroid production. Similarly, in humans, administration of IL-1Ra 
decreases serum cortisol of healthy45 and obese individuals46.
Since IL-1β antagonism improves β-cell function31 in subjects with type 2 diabetes and insulin sensitivity in 
obese individuals47, and since IL-1β is increased in women with GDM14,36, we aimed to study the effect of IL-1β 
antagonism in this condition. Therefore, we established a mouse model of GDM and tested the effect of blocking 
IL-1β in comparison to vehicle-treated pregnant and non-pregnant mice.
Materials and Methods
Mice. All mouse experiments were approved by the cantonal authorities of Basel Stadt, Switzerland and 
research was conducted in accordance with the guidelines for the care and use of animals of the cantonal authori-
ties of Basel Stadt, Switzerland. Naïve female C57BL/6N mice were either purchased from Charles River (Sulzfeld, 
Germany) or originated from our own in-house breeding. Naïve female Lyz2-Cre-specific IL-1β knock out mice 
(Il1bfl/flLyz2-Cre) and Cre-negative littermate controls (WT) originated from our in-house breeding48. All com-
parisons within the groups are comparisons between littermate mice.
Timed-mating. In order to align menstrual cycles and induce estrus in female mice, used bedding material 
from male mice was transferred into female study cages. 2.5 days after cycle synchronization, females were trans-
ferred into the cage of male breeders and returned to their own cage after 24 hrs. The day of plug detection was 
regarded as day 0.5 of pregnancy (Fig. 1B). Unfortunately, plug detection combined with weight analysis turned 
out to be often unspecific in predicting pregnancy, imposing us to use a large number of mice (total number of 
mice for the study was 346). At timed-mating, mice were on average 13.5 weeks old (chow-fed C57BL/6N mice 
and high-fat diet (HFD) -fed Il1bfl/flLyz2-Cre mice and their wild type controls) or 17.5 weeks old (HFD-fed 
C57BL/6N mice) (Fig. 1A).
Anti-IL-1β treatment and diet. If indicated, mice received one single subcutaneous (s.c.) bolus injection 
containing 10 µg/g body weight of a murine anti-IL-1β antibody (BSUR05, with the same specificity as canaki-
numab; kindly provided by Novartis, Switzerland) used in previous studies49, or vehicle on day 7.5 of pregnancy.
If indicated, mice were fed HFD with 60 kJ% fat and 21 kJ% carbohydrates (Lard; EF D12492; ssniff 
Spezialitäten, Soest, Germany) starting at the age of 12 weeks, all other mice received normal rodent-chow diet 
(3436, Provimi Kliba, Kaiseraugst, Switzerland).
Experimental groups. There were 168 chow-fed mice in 10 independent cohorts. We called these cohorts 
“lean” mice. There were 74 HFD-fed mice in 5 independent cohorts in which pregnant mice developed ges-
tational diabetes. We called these cohorts oGDM. There were 61 HFD-fed mice in 4 independent cohorts in 
Figure 1. Schematic representation of the experimental timeline. w = week of age; d = day of pregnancy. (A) 
Timeline of lean mice and obese healthy and obese gestational diabetes mellitus mice. (B) Timeline of all three 
groups during pregnancy.
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which pregnant mice did not develop gestational diabetes. We called these cohorts oGH. There were 43 HFD-fed 
Il1bfl/flLyz2-Cre mice and wild type controls in 3 independent cohorts.
Environmental conditions. All mice had free access to food and water and were housed in a 12-hour light 
and dark cycle with the light phase during the day. Individually ventilated cages (Greenline-Tecniplast) contained 
2–5 animals, environmental enrichment, ABEDD classic 4604 as bedding material and were kept in a specific 
pathogen free facility at 25 °C. Weight and health status was checked on a weekly basis.
Glucose-tolerance testing. Glucose-tolerance testing (GTT) was performed on day 13.5 of pregnancy. For 
GTT, mice were fasted for 6 hours starting in the morning. Fasted mice received an s.c. injection of 2 g glucose per 
kg of body weight. Blood glucose was measured twice per time point prior to, and 15, 30, 60, 90, and 120 minutes 
after glucose application, each with a drop of blood from the tail vein, using FreeStyle Lite glucose meters (Abbott 
AG, Baar, Switzerland). At the first three time points, additional blood samples were collected from the tail vein 
into tubes containing EDTA for later measurement of plasma insulin with the MSD Mouse/Rat Insulin Kit (Meso 
Scale Diagnostics, Rockville MD, USA) according to manufacturer’s instructions.
Sacrifice of mice. Mice were sacrificed in the afternoon of day 14.5 of pregnancy. Serum and tissue for IL-1β 
and steroid hormone measurements and gene expression analyses were obtained at sacrifice.
Serum preparation. Serum was obtained by allowing fresh blood obtained by cardiac puncture to stand for 
30 minutes at room temperature, followed by centrifugation at 10,000 rcf for 20 minutes.
IL-1β measurements of serum and organ extracts. Serum-IL-1β measurements were performed with 
the MSD mouse IL-1β Kit (K152QPD; Meso Scale Diagnostics) according to the “alternative protocol 2” of the 
manufacturer’s instructions.
For tissue preparations, previously weighed pieces of tissue were homogenized with 5 mm stainless steel beads 
(69989; Qiagen, Maryland, USA) in a TissueLyser (85300; Qiagen) in protein lysis buffer containing 20 mM Tris 
buffer pH 7.5, 1% Triton X-100, 150 mM NaCl, 10% glycerol, 10% cOmplete Protease Inhibitor Cocktail (Roche, 
Switzerland), 10 mM Na3VO4, 100 mM NaF, 5 mM PMSF and 5 mM EDTA. The resulting homogenates were 
centrifuged two times at 10,000 rcf for 10 min at 4 °C to pellet insoluble material and the clear protein supernatant 
was collected. IL-1β concentration in supernatants was measured with the MSD mouse IL-1β Kit according to the 
“alternative protocol 2” of the manufacturer’s instructions. The detected IL-1β concentration was normalized to 
the weight of the processed tissue.
IL-1Ra measurements of serum. Serum-IL-1Ra measurements were performed with the mouse IL-1ra 
Quantikine ELISA Kit (MRA00, Biotechne) according to the manufacturer’s instructions.
Serum steroid hormone measurements. Serum steroid hormone levels [corticosterone, 
11-dehydrocorticosterone, 11-deoxycorticosterone, aldosterone, androstenedione, testosterone and proges-
terone] were determined as described previously with minor adaptations50. Briefly, for solid-phase extraction 
(SPE), each serum sample (100 µL) was mixed with protein precipitation solution (100 µL, 0.8 M zinc sulphate in 
water/methanol; 50/50, v/v) that contained (33 nM) deuterium-labeled aldosterone (D7), corticosterone (D8), 
androstenedione (D7) and testosterone (D2) as internal standard. Prior SPE, all samples were diluted to a final 
volume of 1 mL with water and incubated in a thermoshaker (10 min at 4 °C, 1300 rpm). Following incubation, 
samples were centrifuged (10 min at 16,000 rcf at 4 °C), and supernatants (950 µL) were transferred to Oasis HBL 
SPE (1 cc) cartridges (Waters, Milford, MA, USA), preconditioned with methanol and water (3 × 1 mL each). 
Samples were washed with water (1 mL) and methanol/water (2 × 1 mL, 10/90, v/v). Steroids were eluted with 
methanol (2 × 0,75 mL), evaporated to dryness (3 hours, 35 °C) and reconstituted in methanol (25 µL, 10 min, 
4 °C, 1300 rpm). Steroid content was analyzed by ultra-high pressure liquid chromatography-tandem mass spec-
trometry (UPLC-MS/MS) using an Agilent 1290 UPLC coupled to an Agilent 6490 triple quadrupole mass spec-
trometer equipped with a jet-stream electrospray ionization interface (Agilent Technologies, Santa Clara, CA, 
USA). Analyte separation was achieved using a reverse-phase column (1.7 µm, 2.1 mm × 150 mm; Acquity UPLC 
BEH C18; Waters). Data acquisition and quantitative analysis were performed by MassHunter (Version B.07.01, 
Agilent Technologies).
Ribonucleic acid (RNA) extraction and quantitative PCR (qPCR). Pieces of tissue (20–30 µg) 
were homogenized with 5 mm stainless steel beads (69989; Qiagen) in a TissueLyser (85300; Qiagen) in 350 µl 
lysis buffer of the RNA extraction kit and total RNA was isolated using the NucleoSpin RNA II Kit (Macherey 
Nagel, Düren, Germany) according to the manufacturer’s instructions. Complementary deoxyribonucleic acid 
was prepared using the GoScript Reverse Transcriptase (A5003, Promega, Catalys, Switzerland) and used for 
Taqman qPCR or Sybr Green qPCR on a ViiA 7 real-time PCR system (Thermo Fischer Scientific, USA). For 
Taqman qPCR we used GoTaq polymerase mixes (A6102, GoTaq Probe qPCR Master mix, Promega, Dübendorf, 
Switzerland) and the following ABI Taqman probes (Thermo Fisher Scientific, Reinach, Switzerland): Il1b: 
Mm00434228, 18s: Hs99999901_s1. For Sybr Green qPCR we used GoTaq qPCR Master Mix (A6002, Promega, 
Catalys) and the following primers: 18S fw 5′-GGGAGCCTGAGAAACGGC-3′ and rev 5′-GGGTCGGGA 
GTGGGTAATTT-3′, Cyp11b2 fw 5′-CGTGGCCTGAGACGTGGTGT-3′ and rev 5′-CATCCATGGTAAG 
GCTCCCACGA-3′, NK1.1 (Gene name: Klrb1c) fw 5′-GCTGTGCTGGGCTCATCCT-3′ and rev 5′-TTGATGGT 
TTTTGTACTAAGACTCGCA-3′, Cd74 fw 5′-CCCAGGACCATGTGATGCAT-3′ and rev 5′-CTTAAGATGCTT 
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CAGATTCTCT-3′, Cd68 fw 5′-GCAGCACAGTGGACATTCAT-3′ and rev 5′-AGAGAAACATGGCC 
CGAAGT-3′, Adgre fw 5′-GCCCAGGAGTGGAATGTCAA-3′ and rev 5′-CAGACACTCATCAACATCTGCG-3′.
Statistics. Data are expressed as means (SEM). The following statistical tests were performed where appro-
priate: Two-way ANOVA followed by Sidak’s multiple comparison analysis, Mann-Whitney U test, Dunn’s 
Kruskal-Wallis multiple comparisons. Tests as stated in the figure legends were used for comparison of groups 
and p < 0.05 were considered significant. Data analysis was performed using GraphPad Prism v7.0d software.
Ethics. All animal experiments were approved by the cantonal authorities of Basel, Switzerland (license num-
ber 2695_28261).
Results
Mouse model for gestational diabetes mellitus. To establish a rodent model for GDM, we fed pregnant 
mice of different ages with standard chow or HFD and categorized them according to their glucose tolerance.
Glucose clearance in chow-fed, hereafter called “lean”, pregnant mice with the average mating age of 13.5 
weeks was delayed compared to non-pregnant controls (Fig. 2A) despite (insufficiently) increased insulin secre-
tion (Fig. 2D,G).
To induce GDM, we fed older mice (12 weeks of age) an HFD for 8 weeks before mating (average age at 
mating: 17.5 weeks) and during pregnancy, thereby applying two major risk factors for GDM. We then divided 
the HFD-fed cohorts depending on the development of impaired glucose tolerance. Similar to the frequencies 
observed in human obese pregnancies (39%), we saw a marked impairment of glucose tolerance in five of nine 
(55%) HFD-fed cohorts (average number of animals per cohort: 17). Glucose tolerance was markedly impaired, 
with a more than 20% higher rise in blood glucose in pregnant mice compared to non-pregnant controls (average 
AUC impairment by pregnancy: 37.25%, 99% CI 6.57%) (Fig. 2B). Plasma insulin was significantly (P < 0.05) 
increased only 30 min after the glucose bolus and insulin AUC was not different compared to non-pregnant 
controls (Fig. 2E,H). These HFD-fed cohorts are hereinafter referred to as “obese gestational diabetes mellitus” 
(oGDM) mice. In contrast, in four HFD-fed cohorts glucose tolerance was not impaired in pregnant mice com-
pared to the non-pregnant controls (average AUC impairment by pregnancy: 9.07%, 99% CI 10.00%) (Fig. 2C) 
probably due to a significant (P < 0.05) increase in insulin secretion (Fig. 2F,I). These cohorts are herein referred 
to as “obese gestation healthy” (oGH).
As expected, pregnancy increased body weight in all three models by approximately 20%, although HFD 
feeding masked some of this effect (Fig. 2J). Importantly, body weight in pregnant oGDM and oGH mice was 
comparable.
An interesting side observation was that fertility was significantly (P < 0.05) lower in HFD-fed mice compared 
to lean mice (Fig. 2K).
IL-1β is increased in pregnant mice. We then tested the hypothesis that IL-1β may impair glucose 
tolerance during pregnancy. First, we measured serum IL-1β in pregnant mice compared to their respective 
non-pregnant controls. IL-1β was elevated in all three pregnancy models (Fig. 3A–C) with a doubling of IL-1β 
levels in all three groups.
To track the source of the increase in circulating IL-1β, we measured IL-1β in various tissues relevant to 
metabolism and pregnancy. There was no difference in Il1b gene expression and protein level in subcutaneous or 
gonadal fat tissue, nor in spleen, liver or pancreatic islets between pregnant mice and non-pregnant controls (data 
not shown). In the uterus, however, Il1b gene expression was increased in pregnant lean and oGDM mice but not 
in pregnant oGH mice compared to their corresponding non-pregnant control (Fig. 3D–F). To test if this increase 
in gene expression translates to protein level, we also measured IL-1β content per uterus. The total amount of 
IL-1β per organ was higher in pregnant oGMD and oGH mice compared to corresponding non-pregnant con-
trols, but this increase was lower in oGH (Fig. 3G). We also measured IL-1β protein content of placentae in 
oGDM and oGH mice, which was similar to that of the uterus in pregnant mice (Supplement Fig. S1A). This 
indicates that the uterus with the placentae is a probable source of increased IL-1β during pregnancy.
To substantiate an increase in biologically active IL-1β, we measured the expression of immune cell markers 
in the uterus. Compared to non-pregnant controls, oGDM mice had increased gene expression of immune cell 
markers, such as NK1.1 for natural killer cells, Cd74 for dendritic cells and Cd68 and Adgre for macrophages 
(Fig. 3H). In pregnant oGH mice, only uterine gene expression of Cd68 and Adgre but not of NK1.1 and Cd74 was 
increased (Fig. 3I).
IL-1β antagonism improves glycaemia in GDM. To test if IL-1β has a causal role in the 
pregnancy-associated impairment of glucose tolerance, we injected a neutralizing anti-IL-1β antibody 
(anti-IL-1β) into pregnant mice on day 7.5 of pregnancy and corresponding non-pregnant controls to block 
IL-1β action (Fig. 1B). Of note, the injections occurred before the pregnancy could be verified, forcing us to 
increase the number of experiments but with the benefit of better randomization. In non-pregnant mice as well 
as in pregnant lean and pregnant oGH mice, injection of anti-IL-β had no effect on glucose tolerance or basal and 
glucose-stimulated insulin secretion (Fig. 4A,C,D,F). In contrast, in pregnant oGDM mice, injection of anti-IL-1β 
significantly (P < 0.01) improved glucose tolerance (Fig. 4B), while basal and glucose-stimulated insulin secre-
tion did not differ (Fig. 4E), pointing to changes in insulin sensitivity. Anti-IL-1β injections did not influence 
maternal or fetal body weight in either of the three pregnancy models (Fig. 4G–J). To investigate a potential 
counter-regulatory mechanism in the IL-1 pathway during GDM, we measured circulating IL-1Ra in oGDM 
and oGH mice. IL-1Ra was comparable between anti-IL-1β-treated or not pregnant mice and their respective 
non-pregnant controls (Supplement Fig. S1B,C).
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To test the involvement of the myeloid compartment as a possible source of IL-1β in GDM we used myeloid 
cell-specific IL-1β knock out mice. In contrast to oGDM mice injected with anti-IL-1β, HFD-fed pregnant Il1bfl/
flLyz2-Cre knock out mice were not protected from impaired glucose tolerance (Supplement Fig. S1D,E).
Steroid hormones. To test whether IL-β regulates adrenal steroidogenesis and thereby possibly affects insu-
lin resistance during pregnancy, we measured serum concentrations of a panel of steroid hormones in lean and 
oGDM mice and their non-pregnant controls treated with anti-IL-β or vehicle.
Figure 2. Mouse model for gestational diabetes mellitus. Concentration of (A–C) plasma glucose and (D–I) 
insulin during a s.c. GTT. (A,D,G); lean mice (non-pregnant n = 62, pregnant n = 35), (B,E,H); oGDM mice 
(non-pregnant n = 25, pregnant n = 12), (C,F,I); oGH mice (non-pregnant n = 21, pregnant n = 10). (J) 
Body weight was assessed on the day of GTT. (K) Percentage of mice per cohort becoming pregnant after timed-
mating. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 ((A–F) Two-way ANOVA followed by Sidak’s 
multiple comparison analysis, (G–I,K) Mann-Whitney U test, (J) Dunn’s Kruskal-Wallis multiple comparisons).
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Pregnancy increased serum concentrations of progesterone, corticosterone, 11-deoxycorticosterone, aldos-
terone, 11-dehydrocorticosterone, testosterone, androstenedione and 17α-hydroxyprogesterone (Fig. 5A–H, 
Supplement Fig. S1F–O). Although a general pattern pointing to a decrease of these hormones by anti-IL-1β 
appeared, none of these changes were statistically significant. However, in anti-IL-1β treated pregnant oGDM 
mice the corticosterone precursor 11-deoxycorticosterone numerically increased by 22% (Fig. 5D) while cor-
ticosterone (the main glucocorticoid in rodents) itself numerically decreased (Fig. 5F), so that there was a 
tendency to a reduction of corticosterone/11-deoxycorticosterone ratio (Fig. 5I) compared to vehicle treated 
pregnant oGDM mice. Supporting this finding, adrenal gene expression of Cyp11b2, an enzyme that can convert 
11-deoxycorticosterone to corticosterone, was significantly (P < 0.01) increased only in vehicle treated oGDM but 
not following anti-IL-1β therapy (Fig. 5J), while in oGH mice Cyp11b2 was not significantly affected by anti-IL-1β 
antibodies (Fig. 5K). Cyp11b1 that also catalyzes the conversion of 11-deoxycorticosterone to corticosterone was 
not altered by anti-IL-1β treatment (not shown).
Discussion
We established a model for gestational diabetes in mice that has the advantage of integrating two main risk factors 
of the human situation, obesity and aging. This model allowed us to identify IL-1β as a causal driver of impaired 
glucose tolerance in GDM. Indeed, uterine and placental Il1b expression were increased during pregnancy, pos-
sibly contributing to the observed increase in circulating IL-1β. Accordingly, IL-1β antagonism improved gly-
caemia specifically in pregnant oGDM mice and not in non-pregnant controls. This was possibly due to reduced 
conversion of 11-deoxycorticosterone to corticosterone as a consequence of lower Cyp11b2 enzyme expression.
Anti-IL-1β was well tolerated in pregnant mice without any apparent influence on maternal and fetal weight or 
litter size. In humans, two drugs are approved to antagonize the IL-1 system, the anti-IL1β antibody canakinumab 
and the IL-1 receptor antagonist anakinra. Both have shown high safety profiles in long-term studies with only 
few serious adverse events during severe infections. Although some data exist about the use of these drugs during 
human pregnancy51,52, clearly possible benefits versus risks would have to be carefully considered.
Anti-IL-1β had no influence on insulin secretion, pointing to an insulin-sensitizing effect rather than 
an improvement of insulin production in this model. Assessing insulin sensitivity with the gold stand-
ard, the hyperinsulinaemic-euglycaemic clamp, involves anesthaesia and surgery. The resulting stress 
would not be compatible with experimentations during pregnancy precluding us from performing 
hyperinsulinaemic-euglycaemic-clamp studies in these animals.
Figure 3. IL-1β is increased in pregnant mice. IL-1β normalized to average of non-pregnant mice measured 
in afternoon serum of (A) lean (non-pregnant n = 24, pregnant n = 14), (B) oGDM (non-pregnant n = 27, 
pregnant n = 19), (C) oGH (non-pregnant n = 11, pregnant n = 6). Il1b gene expression measured in uterine 
tissue from (D) lean (non-pregnant n = 5, pregnant n = 4), (E) oGDM (non-pregnant n = 14, pregnant n = 7), 
(F) oGH (non-pregnant n = 19, pregnant n = 12) mice. (G) IL-1β protein measured in uterine tissue of oGDM 
(non-pregnant n = 6, pregnant n = 4) and oGH (non-pregnant n = 11, pregnant n = 7) mice. Relative gene 
expression of immune cell markers measured in uterine tissue of (H) oGDM (non-pregnant n = 12, pregnant 
n = 5) and (I) oGH (non-pregnant n = 15, pregnant n = 8) mice. *P < 0.05, **P < 0.01, ****P < 0.0001 ((A–I) 
Mann-Whitney U test).
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Figure 4. IL-1β antagonism improves glycaemia in gestational diabetes mellitus. Concentration of (A–C) 
plasma glucose and (D–F) insulin during a s.c. GTT in (A,D) lean (non-pregnant n = 62, anti-IL-1β treated 
non-pregnant n = 43, pregnant n = 35, anti-IL-1β treated pregnant n = 28), (B,E) oGDM (non-pregnant n = 25, 
anti-IL-1β treated non-pregnant n = 24, pregnant n = 12, anti-IL-1β treated pregnant n = 13) and (C,F) oGH 
(non-pregnant n = 21, anti-IL-1β treated non-pregnant n = 25, pregnant n = 10, anti-IL-1β treated pregnant 
n = 5) mice. Body weight was assessed in (G) lean, (H) oGDM and (I) oGH on the day of GTT. (J) Average 
fetal weight per pregnant mouse was assessed one day after GTT in pregnant lean (pregnant n = 13, anti-IL-1β 
treated pregnant n = 8), oGDM (pregnant n = 12, anti-IL-1β treated pregnant n = 13) and oGH (pregnant 
n = 10, anti-IL-1β treated pregnant n = 5) mice. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 ((A–F) 
Two-way ANOVA followed by Sidak’s multiple comparison analysis (only significance of pregnant vs. pregnant 
anti-IL-1β treated represented), (G–J) Dunn’s Kruskal-Wallis multiple comparisons).
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We observed increased uterine and placental IL-1β expression during pregnancy as well as upregulation of 
markers of natural killer cells (NK1.1), dendritic cells (Cd74) and macrophages (Cd68, Adgre) in oGDM. This 
is in agreement with a previous report of increased immune-cell infiltration in the uterus during pregnancy53. 
Figure 5. Changes in steroid hormones in gestational diabetes mellitus. (A) Progesterone, (C) 
11-deoxycorticosterone and (E) corticosterone (G) aldosterone was measured in serum of non-pregnant 
(n = 8), anti-IL-1β treated non-pregnant (n = 3), pregnant (n = 7) and anti-IL-1β treated pregnant (n = 11) 
lean mice. (B) Progesterone, (D) 11-deoxycorticosterone, (F) corticosterone (H) aldosterone was measured 
in serum of non-pregnant (n = 18), anti-IL-1β treated non-pregnant (n = 17), pregnant (n = 7) and anti-
IL-1β treated pregnant (n = 8) oGDM mice. (I) Corticosterone/11-deoxycorticosterone ratio was calculated 
from the measurements of (D,F). Gene expression of Cyp11b2 was measured in adrenal tissue of (J) oGDM 
(non-pregnant n = 10, anti-IL-1β treated non-pregnant n = 10, pregnant n = 8, anti-IL-1β treated pregnant 
n = 3) and (K) oGH (non-pregnant n = 14, anti-IL-1β treated non-pregnant n = 14, pregnant n = 8, anti-IL-1β 
treated pregnant n = 3) mice. *P < 0.05, **P < 0.01, ***P < 0.001, ((A–G) Dunn’s Kruskal-Wallis multiple 
comparisons, (H–I) Mann-Whitney U test).
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Macrophage markers (Cd68, Adgre) were also upregulated in uterine tissues of oGH pregnant mice compared to 
non-pregnant controls. Further, HFD-fed pregnant Il1bfl/fl Lyz2-Cre knock out mice, which are deficient in mye-
loid derived IL-1β, did not have improved glucose tolerance compared to pregnant wild type mice. These findings 
suggest that natural killer cells or dendritic cells rather than macrophages are a likely cellular source of increased 
uterine IL-1β in GDM. The precise implications of this inflammatory process remain to be shown, but it is likely 
to contribute to uterus growth and possibly to the fetal-maternal immune barrier. In response to metabolic stress 
induced by overfeeding and obesity, these immune cells may become pathologically over-activated54, leading to 
secretion of cytokines such as IL-1β, releavant for glucose homeostasis.
We conclude, that IL-1β, presumably derived from the uterus and the placenta, contribute to the impaired 
glucose tolerance during GDM, possibly via changes in steroid-hormones and subsequent insulin resistance.
Data availability
The data that support the findings of this study are available from the corresponding author upon request.
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